Charles leads ClearView’s diagnostics industry initiatives. This includes work with in vitro diagnostic platform and kit developers, laboratories, and pharma players launching products with companion diagnostics. His expertise is in advising both venture backed and more established clients on commercialization and market access strategies. Over the past 13+ years he has been involved in the launch of over 100+ different test products in the cancer, diabetes, cardiovascular disease, and infectious disease spaces. These tests range from simple point of care technologies to esoteric molecular and next generation sequencing approaches. He has unique knowledge about reimbursement pathways for diagnostic testing including pursuit of novel coding as well as seeking value-based pricing and securing market access for drug diagnostic combinations. For example, he lead a project for AMP that was focused on assessing the cost and value of various next generation sequencing applications. Charles’ prior experience includes several years of working on health policy issues as a legislative aide on Capitol Hill. He also worked for the government affairs office of Genentech and has worked on a National Institutes of Health sponsored clinical trial focused on genetic testing for Alzheimer’s disease. He completed his undergraduate work at Colgate University and received a Masters Degree in Public Policy at Duke University.